Nanjing Hicin Pharmaceutical Co., Ltd.

300584

CNE100002F44

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 01/07/2024 BST			5-day change	1st Jan Change
15.67 ^CNY	+2.08%		+3.64%	-32.69%

06-13	Hicin Pharmaceutical Gets Registration Certificate for Tenofovir Alafenamide Fumarate Tablet	MT
06-12	Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 18 June 2024	CI

Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 18 June 2024

June 12, 2024 at 08:37 pm

Nanjing Hicin Pharmaceutical Co., Ltd. announced final cash dividend (tax included) (A shares) for 2023 of CNY 0.50000000 per 10 shares. The dividend will be payable on 18 June 2024 with Record date of 17 June 2024 and Ex-date of 18 June 2024.

Latest news about Nanjing Hicin Pharmaceutical Co., Ltd.

Hicin Pharmaceutical Gets Registration Certificate for Tenofovir Alafenamide Fumarate Tablet	06-13	MT
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 18 June 2024	06-12	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023	04-24	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	22/08/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/04/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. cancelled the transaction announced on June 10, 2022	12/02/23	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/10/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Management Changes	18/07/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 400 million in funding	09/06/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2021, Payable on May 25, 2022	19/05/22	CI
Nanjing Hicin Pharmaceutical Approves Profit Distribution for 2021	17/05/22	CI
Nanjing Hicin Pharmaceutical Proposes Profit Distribution for 2021	22/04/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	21/04/22	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/10/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	03/08/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 13, 2021	30/04/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2020	08/04/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	07/04/21	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	29/10/20	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	17/08/20	CI
Nanjing Hicin Pharmaceutical Co., Ltd. Announces 2019 Final Distribution Plan to Be Implemented (A Shares), Payable on May 14, 2020	07/05/20	CI

Chart Nanjing Hicin Pharmaceutical Co., Ltd.

Duration

Period

Chart Nanjing Hicin Pharmaceutical Co., Ltd.

More charts

Company Profile

Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NANJING HICIN PHARMACEUTICAL CO., LTD.	-32.69%	253M
ELI LILLY AND COMPANY	+55.55%	823B
NOVO NORDISK A/S	+42.31%	641B
JOHNSON & JOHNSON	-6.83%	352B
MERCK & CO., INC.	+17.15%	324B
ABBVIE INC.	+7.09%	301B
ASTRAZENECA PLC	+14.02%	241B
ROCHE HOLDING AG	+1.64%	223B
NOVARTIS AG	+13.66%	218B
AMGEN INC.	+7.87%	167B

Other Pharmaceuticals